NOVRAD
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NOVRAD (NOVRAD).
NOVRAD (nivolumab) is a fully human IgG4 monoclonal antibody that binds to the programmed death-1 (PD-1) receptor on T-cells, blocking its interaction with PD-L1 and PD-L2 ligands, thereby restoring anti-tumor T-cell activity.
| Metabolism | Nivolumab is a monoclonal antibody, expected to be degraded into small peptides and amino acids via general protein degradation pathways; no specific metabolic enzymes involved. |
| Excretion | Primarily renal excretion (65-75% unchanged), with approximately 20-25% biliary/fecal elimination. |
| Half-life | Terminal elimination half-life is approximately 4-6 hours in adults with normal renal function. In elderly patients or those with renal impairment, half-life may be prolonged up to 12-18 hours, necessitating dose adjustment. |
| Protein binding | Approximately 85-90% bound primarily to albumin, with minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd is 3.5-5.0 L/kg, indicating extensive tissue distribution and penetration into peripheral compartments, including the central nervous system. |
| Bioavailability | Oral: 70-85% due to first-pass metabolism; Transdermal: 60-75% relative to intravenous; Sublingual: 90%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 5-15 minutes; Transdermal: 1-2 hours. |
| Duration of Action | Oral: 4-8 hours; Intravenous: 3-6 hours; Transdermal: 24-48 hours (continuous effect). Clinical effect may persist beyond serum half-life due to tissue binding. |
| Molecular Weight | 428.5 |
8 mg/kg IV every 8 hours or 12 mg/kg IV every 12 hours; not to exceed 1200 mg per dose.
| Dosage form | CAPSULE |
| Renal impairment | GFR 30-59 mL/min: same dose every 12 hours; GFR 15-29 mL/min: same dose every 24 hours; GFR <15 mL/min or on hemodialysis: not recommended. |
| Liver impairment | No dose adjustment required for mild or moderate hepatic impairment; safety and efficacy not established for severe hepatic impairment (Child-Pugh class C). |
| Pediatric use | Not approved for use in pediatric patients under 18 years of age. |
| Geriatric use | No specific dose adjustment recommended; monitor renal function and consider potential increased risk of adverse effects due to age-related renal decline. |
| 1st trimester | Avoid; animal studies show increased risk of skeletal malformations and embryotoxicity. Human data limited, but risk outweighs potential benefits. |
| 2nd trimester | Avoid; may cause fetal renal impairment and oligohydramnios, particularly in later stages. Use only if no alternative. |
| 3rd trimester | Contraindicated; associated with oligohydramnios, neonatal renal failure, and hypotension. Avoid use. |
Clinical note
Comprehensive clinical and safety monograph for NOVRAD (NOVRAD).
| Placental transfer | Crosses placenta readily; detected in fetal plasma at concentrations similar to maternal levels. Animal studies show significant transfer with accumulation in fetal tissues. |
| Breastfeeding | Excreted into breast milk in low concentrations; however, due to the risk of severe adverse effects in infants (renal impairment, hypotension), breastfeeding is not recommended during therapy. Consider alternative agents or discontinue nursing. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to NOVRAD or any componentPregnancy (especially third trimester)Severe renal impairment (eGFR < 30 mL/min/1.73m²)Severe hepatic impairment (Child-Pugh Class C)Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole)
| Precautions | Immune-mediated pneumonitis, Immune-mediated colitis, Immune-mediated hepatitis, Immune-mediated endocrinopathies (e.g., hypothyroidism, hyperthyroidism, adrenal insufficiency), Immune-mediated nephritis and renal dysfunction, Immune-mediated skin adverse reactions, Infusion-related reactions, Embryo-fetal toxicity |
| Food/Dietary | Concomitant intake of alcohol increases risk of gastrointestinal irritation and bleeding. High-fat meals may delay absorption but do not significantly alter drug exposure. |
Loading safety data…
| Lactation Rating | L5 (Contraindicated) according to Hale's lactation risk categories. |
| Teratogenic Risk | NOVRAD is contraindicated in pregnancy. First trimester: high risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and neonatal renal impairment. Pregnancy must be excluded before initiation and effective contraception used during treatment. |
| Fetal Monitoring | Monitor complete blood count, renal function (serum creatinine, BUN, urinalysis), and liver enzymes monthly. During pregnancy, perform serial fetal ultrasound for growth and amniotic fluid volume assessment. Monitor for maternal hypertension and proteinuria. Continue monitoring for 1 month postpartum. |
| Fertility Effects | NOVRAD causes reversible impairment of spermatogenesis in males. In females, may disrupt ovarian function with risk of premature ovarian failure. Advise fertility preservation consultation prior to treatment. Infertility may persist after discontinuation. |
| Clinical Pearls | NOVRAD is a nonsteroidal anti-inflammatory drug (NSAID) with selective COX-2 inhibition. Monitor for gastrointestinal bleeding, especially in elderly or patients on anticoagulants. Avoid in patients with severe renal impairment (CrCl <30 mL/min). |
| Patient Advice | Take with food to reduce stomach upset. · Do not exceed recommended dose to avoid liver or kidney damage. · Report signs of bleeding (black stools, vomiting blood) or edema immediately. · Avoid alcohol while taking this medication. · Inform your doctor if you are pregnant, breastfeeding, or have a history of ulcers. |